About Coherus biosciences
Coherus Biosciences: Revolutionizing the Biologic Medicines Industry
Coherus Biosciences is a leading global biosimilar company that is committed to improving patient lives by expanding access to life-changing biologic medicines. The company was founded in 2010 and has since then been dedicated to developing high-quality biosimilars that are affordable and accessible to patients worldwide.
Biosimilars are biological products that are highly similar to an already approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency. They offer a more cost-effective alternative to expensive biologic medicines while maintaining the same level of efficacy and safety.
Coherus Biosciences has a robust pipeline of biosimilar products across various therapeutic areas such as oncology, immunology, ophthalmology, and nephrology. The company's flagship product is UDENYCA® (pegfilgrastim-cbqv), which is a biosimilar version of Neulasta® used for the treatment of chemotherapy-induced neutropenia.
UDENYCA® was approved by the US Food and Drug Administration (FDA) in November 2018 and has since then become one of the most successful launches in the history of biosimilars. It has been widely adopted by healthcare providers due to its high quality, reliability, affordability, and accessibility.
In addition to UDENYCA®, Coherus Biosciences also offers other biosimilar products such as CHS-1420 (adalimumab), CHS-0214 (etanercept), CHS-3351 (ranibizumab), CHS-2020 (insulin glargine), among others. These products have either been approved or are currently under review by regulatory agencies worldwide.
The success of Coherus Biosciences can be attributed to its strong focus on research and development (R&D). The company invests heavily in R&D activities aimed at developing innovative solutions that address unmet medical needs while ensuring patient safety. Its state-of-the-art facilities located in California house some of the best scientists who work tirelessly towards discovering new breakthroughs in biotechnology.
Apart from R&D activities, Coherus Biosciences also places great emphasis on partnerships with other companies within the industry. These partnerships enable them to leverage their expertise while sharing knowledge on best practices for developing high-quality biosimilars.
In conclusion, Coherus Biosciences is revolutionizing the biologic medicines industry through its commitment towards improving patient lives by expanding access to life-changing biologic medicines at an affordable cost without compromising quality or efficacy. With its robust pipeline of innovative biosimilar products across various therapeutic areas coupled with strong R&D capabilities backed up by strategic partnerships within the industry; it's no surprise why they're considered one of today's leading global players within this space!